MHRA puts technology in the spotlight in 2024/25 business plan
The MHRA’s 2024/25 business plan focuses on improving service delivery for its customers, enabling access to new technologies.
Business & Regulation
J&J clinches EC approval for first single-pill PAH combo
Epigenetic drugs show 375% increase in Series A venture financing in 2024
Oncternal stock crashes by 60% as it lays off staff and scraps trials
Moderna cuts five programmes to save $1.1bn in R&D costs
Men taking valproate and their partners warned to use contraception by MHRA
BioMarin lays off 225 employees in restructuring efforts
US government unveils finalised drug prices under Inflation Reduction Act
